WuXi Biologics (Cayman) Inc. (HKG:2269)
Hong Kong · Delayed Price · Currency is HKD 47.50
-1.34 (-2.74%)
Sep 10, 2026, 4:08 PM HKT
WuXi Biologics Ratios and Metrics
Market cap in millions HKD. Fiscal year is January - December.
Millions HKD. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 9, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 194,928 | 129,960 | 72,100 | 124,993 | 252,882 | 390,943 | |
Market Cap Growth | 27.37% | 80.25% | -42.32% | -50.57% | -35.32% | -6.90% |
Enterprise Value | 190,480 | 126,322 | 71,052 | 122,776 | 247,673 | 380,146 |
Last Close Price | 47.50 | 31.44 | 17.56 | 29.60 | 59.85 | 92.55 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 9, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 34.74 | 23.79 | 20.19 | 33.37 | 50.61 | 93.99 |
Forward PE | 23.91 | 21.64 | 17.09 | 22.71 | 37.41 | 77.91 |
PS Ratio | 7.15 | 5.36 | 3.63 | 6.66 | 14.65 | 30.95 |
PB Ratio | 3.10 | 2.20 | 1.49 | 2.58 | 6.18 | 9.74 |
P/TBV Ratio | 3.75 | 2.58 | 1.70 | 2.96 | 6.79 | 10.56 |
P/FCF Ratio | - | 43.97 | 52.62 | 182.37 | - | - |
P/OCF Ratio | - | 18.42 | 12.99 | 24.31 | 40.37 | 92.82 |
PEG Ratio | 1.13 | 1.13 | 1.99 | 1.39 | 1.02 | 1.99 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 9, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 6.98 | 5.21 | 3.58 | 6.54 | 14.35 | 30.10 |
EV/EBITDA Ratio | 18.66 | 14.33 | 11.42 | 22.61 | 43.22 | 85.50 |
EV/EBIT Ratio | 21.57 | 17.08 | 14.56 | 28.34 | 50.36 | 97.69 |
EV/FCF Ratio | - | 42.74 | 51.85 | 179.13 | - | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 9, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.05 | 0.06 | 0.11 | 0.10 | 0.12 | 0.13 |
Debt / EBITDA Ratio | 0.31 | 0.38 | 0.82 | 0.89 | 0.86 | 1.18 |
Debt / FCF Ratio | - | 1.17 | 3.84 | 7.33 | - | - |
Net Debt / Equity Ratio | -0.19 | -0.24 | -0.13 | -0.15 | -0.12 | -0.21 |
Net Debt / EBITDA Ratio | -1.16 | -1.59 | -0.99 | -1.36 | -0.85 | -1.89 |
Net Debt / FCF Ratio | - | -4.75 | -4.48 | -10.74 | 13.14 | 2.22 |
Asset Turnover | 0.38 | 0.36 | 0.33 | 0.32 | 0.33 | 0.28 |
Inventory Turnover | 7.27 | 8.11 | 6.71 | 5.04 | 4.31 | 3.94 |
Quick Ratio | 2.64 | 2.97 | 1.98 | 2.35 | 1.56 | 1.85 |
Current Ratio | 3.32 | 3.39 | 2.73 | 2.78 | 1.98 | 2.37 |
Return on Equity (ROE) | 11.38% | 11.64% | 8.82% | 8.90% | 13.20% | 13.09% |
Return on Assets (ROA) | 7.60% | 6.88% | 5.05% | 4.63% | 5.81% | 5.43% |
Return on Invested Capital (ROIC) | 13.88% | 13.11% | 9.71% | 9.72% | 12.78% | 13.38% |
Return on Capital Employed (ROCE) | 13.40% | 12.00% | 9.50% | 8.00% | 10.80% | 8.90% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 9, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 2.97% | 4.20% | 4.95% | 3.00% | 1.98% | 1.06% |
FCF Yield | - | 2.27% | 1.90% | 0.55% | -0.15% | -0.97% |
Buyback Yield / Dilution | 0.45% | 1.22% | 2.80% | 0.62% | 1.04% | -5.05% |